{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:38:08Z","timestamp":1784191088294,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.vaccine.2011.08.117","type":"journal-article","created":{"date-parts":[[2011,9,11]],"date-time":"2011-09-11T20:21:24Z","timestamp":1315772484000},"page":"8669-8676","source":"Crossref","is-referenced-by-count":44,"title":["Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO\u00ae"],"prefix":"10.1016","volume":"29","author":[{"given":"Elisabeth","family":"Schuller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Klingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Dubischar-Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Dewasthaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.08.117_bib0005","series-title":"Health information for international travel 2010","first-page":"74","article-title":"Japanese encephalitis","author":"Fischer","year":"2009"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","article-title":"Japanese encephalitis","volume":"68","author":"Solomon","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0015","first-page":"331","article-title":"Japanese encephalitis vaccines","volume":"81","author":"World Health Organization","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0020","series-title":"Japanese encephalitis vaccines","year":"2008"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0025","series-title":"Emerging infections 8","first-page":"93","article-title":"Japanese encephalitis prevention and control: advances, challenges, and new initiatives","author":"Fischer","year":"2008"},{"issue":"RR-1","key":"10.1016\/j.vaccine.2011.08.117_bib0030","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"43","author":"CDC","year":"1994","journal-title":"MMWR"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2011.08.117_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0264-410X(00)00037-2","article-title":"New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO\/CVI meeting, Bangkok, Thailand, 13\u201315 October 1998","volume":"18","author":"Tsai","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0040","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0140-6736(91)92707-9","article-title":"Side-effects with Japanese encephalitis vaccine","volume":"337","author":"Anderson","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0045","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0140-6736(91)91531-X","article-title":"Adverse reactions to Japanese encephalitis vaccine","volume":"338","author":"Ruff","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0050","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/0140-6736(90)91036-A","article-title":"Further experience with Japanese encephalitis vaccine","volume":"335","author":"Sanchez","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/clinids\/24.2.265","article-title":"Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine","volume":"24","author":"Berg","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3201\/eid0601.000103","article-title":"Japanese encephalitis immunization in South Korea: past, present, and future","volume":"6","author":"Sohn","year":"2000","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/milmed\/164.2.157","article-title":"Sudden death after typhoid and Japanese encephalitis vaccination in a young male taking pseudoephedrine","volume":"164","author":"Franklin","year":"1999","journal-title":"Mil Med"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0264-410X(96)00170-3","article-title":"Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines","volume":"15","author":"Sakaguchi","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0075","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0264-410X(97)00152-7","article-title":"Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines","volume":"16","author":"Sakaguchi","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0080","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1034\/j.1398-9995.2001.056008804.x","article-title":"Anaphylaxis to Japanese encephalitis vaccine","volume":"56","author":"Sakaguchi","year":"2001","journal-title":"Allergy"},{"issue":"March (RR\u20131)","key":"10.1016\/j.vaccine.2011.08.117_bib0085","first-page":"1","article-title":"Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Fischer","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2011.08.117_bib0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003495-200969010-00008","article-title":"Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]","volume":"69","author":"Duggan","year":"2009","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.vaccine.2011.08.117_bib0095","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1586\/erv.09.112","article-title":"IXIARO: a new vaccine against Japanese encephalitis","volume":"8","author":"Jelinek","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"39","key":"10.1016\/j.vaccine.2011.08.117_bib0100","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.vaccine.2010.07.040","article-title":"Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0105","unstructured":"IMOJEV Australian public assessment report November 2010. www.tga.gov.au\/pdf\/auspar\/auspar-imojev.pdf. [accessed 30.06.11]."},{"issue":"December (9602)","key":"10.1016\/j.vaccine.2011.08.117_bib0110","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2011.08.117_bib0115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2011.08.117_bib0120","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"issue":"July (33)","key":"10.1016\/j.vaccine.2011.08.117_bib0125","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1016\/j.vaccine.2009.05.034","article-title":"Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study","volume":"27","author":"Kaltenb\u00f6ck","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0130","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.vaccine.2008.05.081","article-title":"Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study","volume":"26","author":"Schuller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0135","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0140","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.vaccine.2011.01.058","article-title":"Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO\u00ae, IC51","volume":"29","author":"Eder","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0145","series-title":"Statistics with confidence. Confidence intervals and statistical guidelines","first-page":"45","article-title":"Proportions and their differences","author":"Newcombe","year":"2007"},{"issue":"May (6)","key":"10.1016\/j.vaccine.2011.08.117_bib0150","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The Vaccine Adverse Event Reporting System (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.08.117_bib0155","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0160","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2011.08.117_bib0165","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/S0264-410X(03)00404-3","article-title":"Adverse event reporting rates following tetanus-diphteria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS), 1991\u20131997","volume":"21","author":"Lloyd","year":"2003","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2011.08.117_bib0170","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0175","unstructured":"MHRA Public Assessment Report. Swine flu vaccines and antiviral medicines: UK post-pandemic safety review, February 2011. http:\/\/www.mhra.gov.uk\/Safetyinformation\/Generalsafetyinformationandadvice\/Product-specificinformationandadvice\/Product-specificinformationandadvice%E2%80%93M%E2%80%93T\/Swinefluinformation\/index.htm. [accessed 13.04.11]."},{"key":"10.1016\/j.vaccine.2011.08.117_bib0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2010.10.016","article-title":"Adverse event reports following Japanese encephalitis vaccination in the United States, 1999\u20132009","volume":"29","author":"Lindsey","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0185","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/651271","article-title":"Japanese encephalitis: new options for active immunization","volume":"50","author":"Halstead","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.08.117_bib0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2011.08.117_bib0195","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.vaccine.2006.05.130","article-title":"Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004","volume":"25","author":"Nakayama","year":"2007","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11013946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11013946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T13:50:14Z","timestamp":1741614614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11013946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":39,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0264410X11013946"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.08.117","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}